Exclusive Summary

• Innovative Delivery Systems: World's first attempt at nebulized delivery of oncolytic virus for lung tumors, offering a non-invasive alternative to intratumoral injection with higher compliance and safety.
• Unique NK Cell-Dependent Mechanism: Unlike T-cell reliant competitors, UB084 functions primarily through NK cells and enhances antigen presentation, making it effective in T-cell exhausted microenvironments.
• Dual Regulatory Clearance & Strong Data: FDA (USA) and CDE (China) IND approvals secured; monotherapy IIT results show impressive efficacy (ORR 27.3%, DCR 81.8%), reportedly outperforming historical PD-1 monotherapy data.
• Converting "Cold" Tumors: Demonstrates capability to reverse PD-L1 expression and actively recruit immune cells, ideal for improving outcomes in refractory Solid Tumors like Recurrent GBM and TNBC.
• Validated Safety Profile: Excellent safety profile observed in dose escalation phases with viral shedding data consistent with expectations, supporting its potential for broad clinical application.

Asset Materials

Contact Us for Full Materials